Guidant (Indianapolis) said that the FDA has approved an expanded indication for the companys portfolio of cardiac resynchronization therapy defibrillators (CRT-D).
Browse by Speciality Area
All Access Subscription
Get unlimited access to our full publication and article library.
Get Access NowInterested in Group Sales? Learn more